Oncologists Embrace Part B Demo, Amgen Says; Big Test In Two Months
Executive Summary
The Medicare Part B market is holding up well in the early weeks of 2005 thanks to a $300 mil. demonstration project unveiled in November, Amgen told analysts Jan. 27 in New York
You may also be interested in...
Amgen Vectibix Assistance Program May Balance Part B Pricing Pressures
Amgen's pricing strategy for its colorectal cancer therapy Vectibix appears to balance the competing pricing pressures created by Medicare Part B's average sales price-based reimbursement methodology
Amgen Vectibix Assistance Program May Balance Part B Pricing Pressures
Amgen's pricing strategy for its colorectal cancer therapy Vectibix appears to balance the competing pricing pressures created by Medicare Part B's average sales price-based reimbursement methodology
CMS Extends Oncology Demo, Shifts Focus To Clinical Guideline Adherence
The Centers for Medicare & Medicaid Services is revising its cancer "quality of care" demonstration project to evaluate oncologists' adherence to evidence-based practice guidelines